当前位置:药药网 / 数据中心 / 儿科研究特征电子表格
Linzess capsules
儿科标签批准日期
2021/8/24 0:00:00
特定指示/秒
Irritable bowel syndrome with constipation
标签更改摘要
- Safety and effectiveness in patients less than 18 years of age have not been established.
- Contraindicated in patients less than 2 years of age. In nonclinical studies, deaths occurred within 24 hours in neonatal mice (human age equivalent of approximately 0 to 28 days) following oral administration of linaclotide which increased fluid secretion as a consequence of age-dependent elevated GC-C agonism resulting in rapid and severe dehydration, as described in Juvenile Animal Toxicity Data.
- A GC-C ontogeny study measured GC-C mRNA expression levels in duodenal and colonic mucosal tissue samples from children aged 6 months to less than 18 years (N=99) to evaluate the risk of diarrhea and severe dehydration due to GC-C agonism in children. The results showed no age-dependent trend in GC-C intestinal expression in children 2 to less than 18 years. However, there are insufficient data available on GC-C intestinal expression in children less than 2 years to assess the risk of developing diarrhea and its potentially serious consequences.
- Information on safety, including a revised boxed warning, and clinical trial.
- Postmarketing study.
治疗类别
Irritable Bowel Syndrome